Richard M. Stone, MD

Articles

Unmet Needs and Future Perspectives in AML

June 23rd 2022

Richard Stone, MD, and Eunice Wang, MD, share upcoming treatment advances they look forward to for patients with acute myeloid leukemia (AML).

Targeted Therapy in Patients with AML and IDH1/IDH2 Mutations

June 23rd 2022

An overview of treatment options in patients who present with IDH1/IDH2 mutations and how to manage treatment-related adverse events.

Importance of Molecular Testing in Acute Myeloid Leukemia to Guide Treatment

June 16th 2022

Richard Stone, MD, and Eunice Wang, MD, explain how molecular biomarker testing influences their treatment decision-making in patients with acute myeloid leukemia (AML).

Patient Profile 2: Patient with de novo AML and IDH2 Mutation

June 16th 2022

Drs Richard Stone and Eunice Wang review the clinical profile of a 67-year-old man with newly diagnosed acute myeloid leukemia (AML) and an IDH2 mutation.

Role of MRD in Treatment Decision Making in AML

June 9th 2022

Two experts discuss the clinical implications of minimal residual disease (MRD) and how it has affected treatment for patients with acute myeloid leukemia (AML).

Considerations for Venetoclax + Azacitidine Administration and AE Management

June 9th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

Selecting the Right Patients for CPX-351 or Venetoclax + Azacitidine in AML

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

CPX-351 in Treatment of AML and Clinical Considerations

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

May 26th 2022

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

Secondary Acute Myeloid Leukemia (AML): Overview

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

Dr. Stone on the Promise of Menin Inhibitors in AML

March 17th 2021

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Dr. Stone on Combinations With Venetoclax in AML

May 2nd 2020

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Stone on Monitoring Patients With AML

November 15th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

Dr. Stone on MRD in Hematologic Malignancies

October 27th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

Dr. Stone Discusses Monitoring MRD in AML

October 11th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

​Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).